Citius Pharmaceuticals, Inc. (CTXR) Reports Fiscal Full Year 2023 Financial Results and Provides Business...
Mino-Lok® Pivotal Phase 3 trial enrollment completed; topline data expected 2Q 2024
LYMPHIR™ BLA resubmission on track for early 2024
Is Citius Pharma a Ten Bagger?
As is From $0.80 to $8.00..
One of our favorite Broker/Dealer Analysts thinks it is..
Bavarian Nordic (BVNRY) Bags $119 Million Order from Joe Biden.
We Were up 80% on Bavarian For a Little While There. The Stock Looks Better Today, Then When we Originally Added...
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy.
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or...
Amazing Sales of Paxlovid (CBS News).
"These medicines have a sweet spot. If the day you get diagnosed COVID you say 'forget it, I'll be fine,' and then...
Everything You Need to Know About FDA’s Priority Review Vouchers Worth $100’s of Millions.
Never Heard of These 'PRV's' but What a Potential Bonanza for the Recipients. They're transferable - as in they can be...
Tax Loss Selling Bargain? Adding Aditxt (ADTX).
Adding Aditxt (ADTX) to the upcoming "2022 Biotech 6-Pack, Stocks We Expect to Double" Watch List.
The Race to Develop Therapeutics for COVID. The Small Caps Fight for a Treatment...
The Second Wave: Biopharma Players Race to Develop Therapeutics for COVID-19 (BioSPace) December 21.
Revive Therapeutics (RVTTF), RedHill BioPharma...
Revive Therapeutics (RVVTF, RVV.CN) in Discussions to Secure Supply of 5 Billion Bucillamine Tablets.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19
Not wanting to be caught...
Mitesco (MITI) Sets Opening Dates for New Minneapolis Clinics, Additional Sites in Minneapolis and...
MINNEAPOLIS, MN, Sept. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Mitesco, Inc. (OTCQB:MITI) ("Mitesco" or the "Company"), a leading operator of wellness clinics...
Latest article
Nine Page Summary Report on GeoVax (GOVX)
This is a great long-term story. We’re telling you.
(March 2024) When we finished writing our earlier...
GeoVax (GOVX) Provides First Half 2024 Business Update.
Award of BARDA Project NextGen contract represents a significant milestone event;
Total value...
Reverse Split Mania! Solgenix (SNGX) Jumps 448% After 1:16.
Can You Imagine Selling Solgenix at $2.00 yesterday.
And to be honest, news wasn't all that big - such...
